Drug Repurposing of Loratadine as a DNMT1 Inhibitor: Comparative Evaluation with Cisplatin in Patient-Derived Oral Squamous Cell Carcinoma Cells. Precision Medicine Communications, [S. l.], v. 4, n. 2, p. 125–137, 2024. DOI: 10.55627/pmc.004.02.1083. Disponível em: https://rootspress.org/journals/PMC/article/view/1083. Acesso em: 3 apr. 2026.